Rights and permissions
About this article
Cite this article
Drotrecogin alfa “cost effective option” in severe sepsis in the UK. Pharmacoecon. Outcomes News 476, 5 (2005). https://doi.org/10.2165/00151234-200504760-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504760-00006